Surrozen, Inc./DE Operating Lease, Weighted Average Discount Rate, Percent
Surrozen, Inc./DE (SRZN) had Operating Lease, Weighted Average Discount Rate, Percent of 8.25% as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-03-23
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 8.25%.
- 2024-12-31: Operating Lease, Weighted Average Discount Rate, Percent 8.25%.
- 2023-12-31: Operating Lease, Weighted Average Discount Rate, Percent 8.48%.
- 2022-12-31: Operating Lease, Weighted Average Discount Rate, Percent 8.48%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2025-12-31 | 8.25% 10-K · filed 2026-03-23 |
| 2024-12-31 | 8.25% 10-K · filed 2026-03-23 |
| 2023-12-31 | 8.48% 10-K · filed 2025-03-31 |
| 2022-12-31 | 8.48% 10-K · filed 2024-04-10 |
| 2021-12-31 | 8.43% 10-K · filed 2023-03-31 |
| 2020-12-31 | 8.40% 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |